By Stewart Bishop ( January 4, 2016, 9:29 PM EST) -- An Indiana federal judge on Monday quashed a securities class action claiming Endocyte Inc. lied about the effectiveness of a cancer drug tied to a $1 billion deal with Merck & Co. Inc. in order to inflate Endocyte's stock ahead of a public offering, saying the allegations cannot rest on a sole confidential witness....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.